Journal of Nuclear Medicine: 60 (11)

November 1, 2019; Volume 60,Issue 11

Cover image

FEATURED ARTICLE

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Jorge Carrasquillo et al. See page 1517.

Refining PSMA targeting: setting molar activity levels to minimize normal tissue adverse effects. Fumihiko Soeda et al. See page 1594.

In this issue

Issue highlights

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
Impact of ¹⁸F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice
Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
Radioactive Iodine Treatment and Cancer Mortality in Hyperthyroid Patients: Questioning Standard Clinical Practice Requires Indisputable Scientific Data

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to